# Rivaroxaban

## XARELTO 15mg

| 藥物代碼 | OXAR |
| :--- | :--- |
| 適應症 | Xarelto 10 mg Prevention of Venous Thrombosis\(VTE\) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15 mg & 20 mg Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation w/ ≧1 risk factors eg CHF, HTN, age ≧75 yr, DM, prior stroke or transient ischaemic attack. Treatment of Deep Venous Thrombosis \(DVT\) & PE, & prevention of recurrent DVT & PE following an acute DVT in adults. |
| 副作用 | Anemia, dizziness, headache, syncope, eye haemorrhage, tachycardia, hypotension, haematoma, epistaxis, GI disorders, pruritus, pain in extremity, urogenital tract haemorrhage, fever, peripheral oedema, decreased general strength & energy, increased transaminases, postprocedural haemorrhage. |
| 禁忌 | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation. |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest moderate risk |
| 附帶說明 | \[仿單\]無孕婦使用的安全性與有效性資料,動物實驗中顯現生殖性毒性,且本藥可以通過胎盤, 懷孕婦女禁止使用. 具生育能力婦女應採取有效的避孕措施. |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | \[仿單\]無授乳婦使用的安全性與有效性資料,動物實驗中顯現本藥可以分泌致乳汁中, 因此僅能在停止哺乳後使用. |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Xarelto 2.5mg

| 藥物代碼 | OXAR25 |
| :--- | :--- |
| 適應症 | Cardiovascular event risk; Prophylaxis of Peripheral arterial occlusive disease and Coronary arteriosclerosis, In combination with aspirin. |
| 副作用 | CommonHematologic: Hemorrhage \(DVT prophylaxis following hip or knee replacement, 5.8%; treatment of DVT or pulmonary embolism, 28.3%; reduction in risk of recurrence of DVT or pulmonary embolism, 13.4% ; prophylaxis of VTE in acutely ill medical patients, 2.9% \)SeriousCardiovascular: Syncope \(1.2% \)Gastrointestinal: Gastrointestinal hemorrhage \(0.5% to 2% \), Upper gastrointestinal bleedingHematologic: Hematoma, Epidural or spinal, Hemorrhage, Major \(Stroke prevention in nonvalvular atrial fibrillation, 3.6%; DVT prophylaxis following hip or knee replacement, 0.3%; treatment of DVT or pulmonary embolism, 1%; reduction in risk of recurrence of DVT or pulmonary embolism, 0.4%; prophylaxis of VTE in acutely ill medical patients, 0.7% \)Immunologic: AngioedemaOther: Drug withdrawal, Stroke and non-CNS embolism. |
| 禁忌 | Active pathological bleeding. Severe hypersensitivity reaction \(eg, anaphylaxis\) to rivaroxaban. Patients with severe hepatic impairment or with any degree of hepatic disease associated with coagulopathy. Patients with severe progressive bleeding \(such as intracranial hemorrhage, gastrointestinal hemorrhage\). PREGNANCY and BREASTFEEDING. Patients with CrCl &lt;15 mL/min. |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest moderate risk |
| 附帶說明 | \[仿單\]無孕婦使用本品的安全性與有效性資料可供參考。在動物試驗中顯示本品有生殖性毒性。 由於潛在的母體毒性與致畸胎性以及內在的出血風險。 加上rivaroxaban可穿過胎盤，懷孕婦女禁止使用本品。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | \[仿單\]無授乳婦女使用本品的安全性與有效性資料可供參考。 在老鼠試驗中顯示rivaroxaban可分泌至母乳中，因此僅能在斷奶後使用本品 |
| 注射劑給藥建議途徑 | AC, AC15, PC, PO, WM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

